Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases

NCT06626919 is registered in ClinicalTrials.gov with Arcellx, Inc. as lead sponsor.

NCT NCT06626919
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06626919 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases
Lead sponsor
Arcellx, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
April 30, 2025
Completion date
April 30, 2028
Enrollment
30 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

autoimmune, autoimmune diseases, autoimmune diseases of the nervous system, muscle weakness, muscular diseases, myasthenia gravis, neuromuscular manifestations